# Patent

## Title
Methods of treating tumoral diseases, or bacterial or viral infections

## Abstract

Novel compounds and their synthesis are described. Methods for using these compounds in the prevention or treatment of cancer, a bacterial infection or a viral infection in a subject are also described.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a divisional of U.S. application Ser. No. 14/046,682, filed Oct. 4, 2013, which claims priority to and the benefit of U.S. Provisional Application Ser. No. 61/709,704, filed on Oct. 4, 2012, the entire contents of each of which are incorporated herein by reference.


STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
This invention was made in part with Government support under Contract No. 1R43NS069213-01/343NS069213-01S1, awarded by the United States' National Institutes of Health. The Government has certain rights in this invention.


CREATE ACT STATEMENT
The inventions disclosed herein were made as a result of activities undertaken within the scope of a joint research agreement between Inhibikase Therapeutics, Inc. and Sphaera Pharma Pvt. Ltd., Haryana, India, which agreement was in effect on or before the invention of the claimed subject matter.
FIELD OF INVENTION
The present invention relates to novel compounds with improved pharmacokinetic and pharmacodynamic properties and a process for the synthesis of these compounds.
BACKGROUND OF INVENTION
Imatinib is the first of a new class of drugs that acts by specifically inhibiting a certain enzyme that is characteristic of a particular cancer cell, rather than non-specifically inhibiting and killing all rapidly dividing cells. Imatinib was a model for other targeted therapies that inhibited the class of enzymes, tyrosine kinases. Imatinib, present as its mesylate salt, multi-targets several pathways and is found to inhibit c-kit, PDGF-R and c-ABL. It is also known for its inhibition of T-cell proliferation stimulated by DCs and PHA. Imatinib Mesylate binds preferentially to ATP-binding sites of the c-kit proto-oncogene product, platelet-derived growth factor receptor (PDGF-R), and Abelson kinase (c-ABL) impeding the ensuing signal transduction. Imatinib, a reversible tyrosine kinase inhibitor, is effective in treatment of chronic myelogenous leukemia (CML), gastrointestinal stromal tumors, eosinophilic disorders, and systemic mast cell disease.




4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide
However, it is desirable to improve pharmacokinetic and if possible the pharmacodynamic parameters of imatinib, to favorably alter the dose and the dosing regimen of imatinib and to reduce the side effects.
SUMMARY OF INVENTION
The present invention comprises novel compounds that, when administered to a patient, provide an active form of imatinib.
The present application provides novel compounds of formula (I) or their pharmaceutically acceptable salts:




wherein:

A and B are independently selected from absent, H or a moiety of Formula (II), with the proviso that at least one of A and B is a moiety of Formula (II);




wherein:

R and R1 are each independently selected from H, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, C1-C8 alkyl and C3-C7 cycloalkyl, wherein in each of the C1-C8 alkyl and C3-C7 cycloalkyl optionally up to three carbon atoms are replaced by a heteroatom group independently selected from O, NR4, S, SO and SO2 (i.e., thereby making a heteroalkyl or heterocyclyl substituent), and wherein the C1-C8 alkyl and C3-C7 cycloalkyl are optionally substituted with from 1 to 4 C1-C8 alkyl, alkoxy, aryl and heteroaryl substituents; or R and R1 taken together with the atom to which they are attached form a 3- to 7-membered ring, wherein the 3- to 7-membered ring optionally contains up to two heteroatom groups selected from O, N R4, S, SO and SO2, and is optionally substituted with 1 to 4 alkoxy, F or Cl substituents;
Y is selected from R2, OR2, NH2, NHR2, and NR2R3;
R2 is selected from alkoxy, aryl, heteroaryl, C1-C8 alkyl and C3-C7 cycloalkyl, wherein in each of the C1-C8 alkyl and C3-C7 cycloalkyl optionally up to three carbon atoms are replaced by a heteroatom group independently selected from O, NR4, S, SO and SO2 (i.e., thereby making a heteroalkyl or heterocyclyl substituent), and wherein the C1-C8 alkyl and C3-C7 cycloalkyl are each optionally substituted with from 1 to 4 C1-C8 alkyl, alkoxy, aryl or heteroaryl substituents;
R3 is selected from alkoxy, aryl, heteroaryl, C1-C8 alkyl and C3-C7 cycloalkyl, wherein in each of the C1-C8 alkyl and C3-C7 cycloalkyl optionally up to three carbon atoms are replaced by a heteroatom group independently selected from O, NR4, S, SO and SO2 (i.e., thereby making a heteroalkyl or heterocyclyl substituent), and wherein the C1-C8 alkyl and C3-C7 cycloalkyl are each optionally substituted with from 1 to 4 C1-C8 alkyl, alkoxy, aryl or heteroaryl; or
R2 and R3 may be taken together with the nitrogen atom to which they are attached to form a 3- to 7-membered ring, wherein the 3- to 7-membered ring optionally contains up to three heteroatom groups selected from O, NR4, S, SO and SO2, and is optionally substituted with alkoxy, F or Cl;
R4 is, independently for each occurrence, selected from H or C1-C8 alkyl; and
X and X1 are each independently an anion or absent, provided that X is absent only when A is absent, and X1 is absent only when B is absent.
The present application also provides a method for the preparation of novel compounds.
The present application also provides compositions comprising novel compounds.
The present application also provides for the use of the compounds for c-ABL, PDGFR and SCFR (c-Kit) inhibition.


DETAILED DESCRIPTION OF THE INVENTION
Accordingly, the present application provides novel compounds of formula (I) or their pharmaceutically acceptable salts and process for producing these compounds.
Compounds of the Present Invention
The present application provides novel compounds of formula (I) or their pharmaceutically acceptable salts:




wherein:

A and B are independently selected from absent, H or a moiety of Formula (II), with the proviso that at least one of A and B is a moiety of Formula (II);




wherein:

R and R1 are each independently selected from H, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, C1-C8 alkyl and C3-C7 cycloalkyl, wherein in each of the C1-C8 alkyl and C3-C7 cycloalkyl optionally up to three carbon atoms are replaced by a heteroatom group independently selected from O, NR4, S, SO and SO2 (i.e., thereby making a heteroalkyl or heterocyclyl substituent), and wherein the C1-C8 alkyl and C3-C7 cycloalkyl are each optionally substituted with from 1 to 4 C1-C8 alkyl, alkoxy, aryl and heteroaryl substituents; or R and R1 taken together with the atom to which they are attached form a 3- to 7-membered ring, wherein the 3- to 7-membered ring optionally contains up to two heteroatom groups selected from O, NR4, S, SO and SO2, and is optionally substituted with 1 to 4 alkoxy, F or Cl substituents;
Y is selected from R2, OR2, NH2, NHR2, and NR2R3;
R2 is selected from alkoxy, aryl, heteroaryl, C1-C8 alkyl and C3-C7 cycloalkyl, wherein in each of the C1-C8 alkyl and C3-C7 cycloalkyl optionally up to three carbon atoms are replaced by a heteroatom group independently selected from O, NR4, S, SO and SO2 (i.e., thereby making a heteroalkyl or heterocyclyl substituent), and wherein the C1-C8 alkyl and C3-C7 cycloalkyl are each optionally substituted with from 1 to 4 C1-C8 alkyl, alkoxy, aryl or heteroaryl substituents;
R3 is selected from alkoxy, aryl, heteroaryl, C1-C8 alkyl and C3-C7 cycloalkyl, wherein in each of the C1-C8 alkyl and C3-C7 cycloalkyl optionally up to three carbon atoms are replaced by a heteroatom group independently selected from O, NR4, S, SO and SO2 (i.e., thereby making a heteroalkyl or heterocyclyl substituent), and wherein the C1-C8 alkyl and C3-C7 cycloalkyl are each optionally substituted with from 1 to 4 C1-C8 alkyl, alkoxy, aryl or heteroaryl; or
R2 and R3 may be taken together with the nitrogen atom to which they are attached to form a 3- to 7-membered ring, wherein the 3- to 7-membered ring optionally contains up to three heteroatom groups selected from O, NR4, S, SO and SO2, and is optionally substituted with alkoxy, F or Cl;
R4 is, independently for each occurrence, selected from H or C1-C8 alkyl; and
X and X1 are each independently an anion or absent, provided that X is absent only when A is absent, and X1 is absent only when B is absent.
In some embodiments, R and R1 are each independently selected from H and C1-C8 alkyl, such as H or methyl. Preferably both R and R1 are H.
In some embodiments, R2 and R3 are independently selected from C1-C8 alkyl and aralkyl. In some such embodiments, R2 and R3 are independently selected from methyl, ethyl, isopropyl, tert-butyl, isobutyl, sec-butyl, 3-methylbut-2-yl, 1-phenylethyl, benzyl or cyclobutyl.
In some embodiments, R4, independently for each occurrence, is selected from H and C1-C8 alkyl.
In some embodiments, X and X1 are each independently halide or sulfonate, such as mesylate and iodide.
Because anions are not covalently attached to the molecule, it should be understood that X and X1 are not necessarily located proximal to the atom bearing A or B, and should be viewed as interchangeable within any given molecule when both are present.
In some embodiments, A is H and B is a moiety of Formula (II).
In some embodiments, A is a moiety of Formula (II) and B is H.
In other embodiments, A is a moiety of Formula (II) and B is absent.
In yet other embodiments, A is absent and B is a moiety of Formula (II).
In certain embodiments, neither A nor B is




Definitions
The term “alkyl” refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, and branched-chain alkyl groups. In preferred embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C30 for straight chains, C3-C30 for branched chains), and more preferably 20 or fewer. In certain embodiments, alkyl groups are lower alkyl groups, e.g. methyl, ethyl, n-propyl, i-propyl, n-butyl and n-pentyl.
Moreover, the term “alkyl” (or “lower alkyl”) as used throughout the specification, examples, and claims is intended to include both “unsubstituted alkyls” and “substituted alkyls”, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C30 for straight chains, C3-C30 for branched chains). In preferred embodiments, the chain has ten or fewer carbon (C1-C10) atoms in its backbone. In other embodiments, the chain has six or fewer carbon (C1-C6) atoms in its backbone.
The term “alkenyl”, as used herein, refers to an aliphatic group containing at least one double bond and is intended to include both “unsubstituted alkenyls” and “substituted alkenyls”, the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the alkenyl group. Such substituents may occur on one or more carbons that are included or not included in one or more double bonds. Moreover, such substituents include all those contemplated for alkyl groups, as discussed below, except where stability is prohibitive. For example, substitution of alkenyl groups by one or more alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl groups is contemplated. In preferred embodiments, a straight chain or branched chain alkenyl has 1-12 carbons in its backbone, preferably 1-8 carbons in its backbone, and more preferably 1-6 carbons in its backbone. Examplary alkenyl groups include allyl, propenyl, butenyl, 2-methyl-2-butenyl, and the like.
The term “alkynyl”, as used herein, refers to an aliphatic group containing at least one triple bond and is intended to include both “unsubstituted alkynyls” and “substituted alkynyls”, the latter of which refers to alkynyl moieties having substituents replacing a hydrogen on one or more carbons of the alkynyl group. Such substituents may occur on one or more carbons that are included or not included in one or more triple bonds. Moreover, such substituents include all those contemplated for alkyl groups, as discussed above, except where stability is prohibitive. For example, substitution of alkynyl groups by one or more alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl groups is contemplated. In preferred embodiments, an alkynyl has 1-12 carbons in its backbone, preferably 1-8 carbons in its backbone, and more preferably 1-6 carbons in its backbone. Exemplary alkynyl groups include propynyl, butynyl, 3-methylpent-1-ynyl, and the like.
The term alkoxy refers to an alkyl group singly bonded to oxygen.
The term “aralkyl”, as used herein, refers to an alkyl group substituted with one or more aryl groups.
The term “aryl”, as used herein, include substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon. Preferably the ring is a 5- to 7-membered ring, more preferably a 6-membered ring. Aryl groups include phenyl, phenol, aniline, naphthyl, biphenyl, anthracenyl and the like.
The term “cycloalkyl”, as used herein, refers to the radical of a saturated aliphatic ring. In preferred embodiments, cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably from 5-7 carbon atoms in the ring structure. Suitable cycloalkyls include cycloheptyl, cyclohexyl, cyclopentyl, cyclobutyl and cyclopropyl.
The terms “cycloalkyl” and “cycloalkenyl” refer to cyclic hydrocarbon groups of 3 to 12 carbon atoms.
The terms “halogen”, “halide” and “halo”, as used herein, mean halogen and include fluoro, chloro, bromo and iodo.
The term “unsaturated ring” includes partially unsaturated and aromatic rings.
The terms “heterocyclyl”, “heterocycle”, “heterocyclo” and “heterocyclic” refer to substituted or unsubstituted non-aromatic ring structures, preferably 3- to 10-membered rings, more preferably 3- to 7-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The heterocyclic group may be attached at any heteroatom or carbon atom of the ring or ring system. Exemplary monocyclic heterocyclic groups include pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane and tetrahydro-1,1-dioxothienyl, triazolyl, triazinyl, and the like. Exemplary bicyclic heterocyclic groups include indolyl, benzothiazolyl, benzoxazolyl, benzodioxolyl, benzothienyl, quinuclidinyl, quinolinyl, tetra-hydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (such as furo [2,3-c] pyridinyl, furo [3,2-b] pyridinyl] or furo [2,3-b] pyridinyl), dihydroisoindolyl, dihydroquinazolinyl (such as 3,4-dihydro-4-oxo-quinazolinyl), tetrahydroquinolinyl and the like. Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, acridinyl, phenanthridinyl, xanthenyl and the like.
The term “heteroalkyl”, as used herein, refers to a saturated or unsaturated chain of carbon atoms including at least one heteroatom (e.g., O, S, or NR4, such as where R4 is H or lower alkyl).
The term “heteroaryl” includes substituted or unsubstituted aromatic single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring structures include at least one heteroatom (e.g., O, N, or S), preferably one to four or one to 3 heteroatoms, more preferably one or two heteroatoms. When two or more heteroatoms are present in a heteroaryl ring, they may be the same or different. The term “heteroaryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Preferred polycyclic ring systems have two cyclic rings in which both of the rings are aromatic. Exemplary heteroaryl groups include pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furyl, thienyl, oxadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, quinolinyl, pyridazinyl, triazolyl, triazinyl, and the like.
The term “alkylene” in this text include both linear and branched, saturated and unsaturated (i.e. containing one double bond) divalent alkylene groups and monovalent alkyl groups, respectively.
The term “alkanol” in this text likewise includes linear and branched, saturated and unsaturated alkyl components of the alkanol groups, in which the hydroxyl groups may be situated at any position on the alkyl moiety. The term “cycloalkanol” includes unsubstituted or substituted (e.g. methyl or ethyl) cyclic alcohols.
The term “alkoxy” is intended to mean a alkyl radical, as defined herein, attached directly to an oxygen atom. Some embodiments are 1 to 5 carbons, some embodiments are 1 to 4 carbons, some embodiments are 1 to 3 carbons and some embodiments are 1 or 2 carbons. Examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, 5-isobutoxy, sec-butoxy, and the like.
The term “heteroatom”, as used herein, means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur.
The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of the invention, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.
As used herein, the term “tumoral disease” refers to a hyperproliferative disease, such as cancer.
As used herein, the term “conjoint administration” means administration of two or more agents to a subject of interest as part of a single therapeutic regimen. The administration(s) can be either simultaneous or sequential, i.e., administering one agent followed by administering of a second (and/or a third one, etc.) at a later time, as long as the agents administered co-exist in the subject being treated, or at least one agent will have the opportunity to act upon the same target tissues of other agents while said target tissues are still under the influence of said other agents. In a certain embodiment, agents to be administered can be included in a single pharmaceutical composition and administered together. In a certain embodiment, the agents are administered simultaneously, including through separate routes. In a certain embodiment, one or more agents are administered continuously, while other agents are administered only at predetermined intervals (such as a single large dosage, or twice a week at smaller dosages, etc.).
The present invention includes within its scope the salts and isomers. Compounds of the present invention may in some cases form salts which are also within the scope of this invention. The term “salt(s)”, as employed herein, denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases. Zwitterions (internal or inner salts) are included within the term “salt(s)” as used herein (and may be formed, for example, where the R substituents comprise an acid moiety such as a carboxyl group). Also included herein are quaternary ammonium salts such as alkylammonium salts. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are useful, for example, in isolation or purification steps which may be employed during preparation. Salts of the compounds may be formed, for example, by reacting a compound with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides, hydrobromides, hydroiodides, 2-hydroxy ethanesulfonates, lactates, maleates, methanesulfonates, 2-naphthalenesulfonates, nicotinates, nitrates, oxalates, pectinates, persulfates, 3-phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (such as those formed with sulfuric acid), sulfonates (such as those mentioned herein), tartrates, thiocyanates, toluenesulfonates, undecanoates, and the like.
Exemplary basic salts (formed, for example, wherein the substituent comprise an acidic moiety such as a carboxyl group) include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as benzathines, dicyclohexylamines, hydrabamines, N-methyl-D-glucamines, N-methyl-D-glucamides, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. The basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (e.g. methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g. decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.
Solvates of the compounds of the invention are also contemplated herein. Solvates of the compounds of formula I are preferably hydrates or other pharmaceutically acceptable solvates.
All stereoisomers of the present compounds, such as those which may exist due to asymmetric carbons on the R substituents of the compound, including enantiomeric and diastereomeric forms, are contemplated within the scope of this invention. Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention may have the S or R configuration.
As used herein, the term “treating” or “treatment” includes reversing, reducing, or arresting the symptoms, clinical signs, and underlying pathology of a condition in manner to improve or stabilize a subject's condition. As used herein, and as well understood in the art, “treatment” is an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.
The present application also envisages within its scope the effect of selection of suitable counter ions. The counter ion of the compounds of the present invention may be chosen by selecting the dissociation constant for the drug capable of ionization within the said pH range. By estimating the ionized and un-ionized drug concentration of any compound (using well established equations such a Henderson-Hasselbach equation), the solubility and consequently the absorption of the drug may be altered.
The compounds of formula II may be divided in three classes i.e. Type I, where Y═OR2; Type II, where Y═R2 and Type III, where Y═NR2R3.
wherein R2 and R3 are as defined above
Non limiting Lists of Type I, Type II and type III reagents are presented below:
Type I Reagents


    
    
        i. chloromethyl isopropyl carbonate
        ii. benzyl chloromethyl carbonate
        iii. chloromethyl morpholinomethyl carbonate
        iv. chloromethyl isobutyl carbonate
        v. chloromethylmethyl carbonate
        vi. (S)-sec-butyl chloromethyl carbonate
        vii. (R)-sec-butyl chloromethyl carbonate
        viii. chloromethyl ((3S,5R)-3,5-dimethylmorpholino)methyl carbonate
        ix. chloromethyl 2-methylcyclopropyl carbonate
        x. chloromethyl2-methoxyethyl carbonate
        xi. chloromethyl propyl carbonate
        xii. chloromethyl cyclobutyl carbonate
        xiii. chloromethyl cyclopropyl carbonate
        xiv. chloromethyl 2,2-dimethylcyclobutyl carbonate
        xv. chloromethyl cyclopentyl carbonate
        xvi. chloromethyl oxetan-3-yl carbonate
        xvii. (S)-chloromethyl tetrahydrofuran-3-yl carbonate
        vviii. chloromethyl cyclohexylmethyl carbonate
        xix. chloromethyl 3-methoxycyclohexyl carbonate
        xx. (R)-chloromethyl tetrahydrofuran-3-yl carbonate
        xxi. chloromethyl ethoxymethyl carbonate
        xxii. chloromethyl oxepan-4-yl carbonate
        xxiii. (1R,2S,4S)-bicyclo[2.2.1]heptan-2-yl chloromethyl carbonate
        xxiv. chloromethyl 2,3-dihydro-1H-inden-1-yl carbonate
        xxv. benzyl chloromethyl carbonate
        xxvi. (S)-chloromethyl 1-phenylethyl carbonate
        xxvii. chloromethyl cyclohexyl carbonate
        xxviii. chloromethyl isobutyl carbonate
        xxix. chloromethyl 4-methylcyclohexyl carbonate
        xxx. chloromethyl 2-(methylthio)ethyl carbonate
        xxxi. chloromethyl 3-methylcyclohexyl carbonate
        xxxii. chloromethylpentan-2-yl carbonate
        xxxiii. chloromethyl neopentyl carbonate
        xxxiv. methyl 1-((chloromethoxy)carbonyloxy)cyclopropanecarboxylate
        xxxv. chloromethyl cyclopropylmethyl carbonate
        xxxvi. chloromethyl 2,2-diethoxyethyl carbonate
        xxxvii. chloromethyl cyclopentylmethyl carbonate
        xxxviii. methyl 2-((chloromethoxy)carbonyloxy)propanoate
        xxxix. (S)-chloromethyl 2,2,4-trimethylcyclopent-3-enyl carbonate
        xl. chloromethyl 1,3-dioxolan-2-yl carbonate
        xli. chloromethyl (2,6-dimethylcyclohexyl)methyl carbonate
        xlii. chloromethyl 2-(tetrahydro-2H-pyran-2-yl)ethyl carbonate
        xliii. chloromethyl(tetrahydro-2H-pyran-4-yl)methyl carbonate
        xliv. chloromethyl tetrahydro-2H-pyran-4-yl carbonate
        xlv. chloromethyl 1-methylcyclopentyl carbonate
        xlvi. chloromethyl 1-cyclopentylethyl carbonate
        xlvii. chloromethyl 3-methylcyclopentyl carbonate
        xlviii. chloromethyl 3,3-dimethylcyclohexyl carbonate
        xlix. chloromethyl 2,5-dimethylcyclohexyl carbonate
        l. chloromethyl 1-(4-methylcyclohexyl)ethyl carbonate
        li. chloromethyl (3-methyloxetan-3-yl)methyl carbonate
        lii. chloromethyl (3-methyloxetan-3-yl)methyl carbonate
        liii. chloromethyl 2-isopropoxyethyl carbonate
        liv. (chloromethyl carbonic) 5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic anhydride
        lv. 4-((chloromethoxy)carbonyloxy)-2-hydroxy-4-oxobutanoic acid
        lvi. chloromethyl 4-formyl-2-methoxyphenyl carbonate
        lvii. chloromethyl 3-oxobutan-2-yl carbonate
        lviii. methyl 4-((chloromethoxy)carbonyloxy)benzoate
        lix. (R)-2-amino-3-((chloromethoxy)carbonyloxy)propanoic acid
        lx. 3-tert-butyl-4-methoxyphenyl chloromethyl carbonate
        lxi. (R)-2-amino-3-(4-((chloromethoxy)carbonyloxy)phenyl)propanoic acid
        lxii. (R)-2-amino-4-((chloromethoxy)carbonyloxy)-4-oxobutanoic acid
        lxiii. (E)-chloromethyl 3,7-dimethylocta-2,6-dienyl carbonate
        lxiv. methyl 4-((chloromethoxy)carbonyloxy)benzoate
        lxv. chloromethyl 2-(4-methylcyclohex-3-enyl)propan-2-yl carbonate
        lxvi. chloromethyl 3,7-dimethylocta-1,6-dien-3-yl carbonate
        lxvii. 4-allyl-2-methoxyphenyl chloromethyl carbonate
        lxviii. chloromethyl (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl carbonate
        lxix. propyl 4-((chloromethoxy)carbonyloxy)benzoate
        lxx. (E)-chloromethyl 3,7-dimethylocta-2,6-dienyl carbonate

Type II Reagents

        i. chloromethyl cyclohexanecarboxylate
        ii. chloromethyl 2-cyclohexylacetate
        iii. chloromethyl 4-methylcyclohexanecarboxylate
        iv. chloromethyl 1-methylcyclohexanecarboxylate
        v. chloromethyl cyclopentanecarboxylate
        vi. chloromethyl 1-(trifluoromethyl)cyclopentanecarboxylate
        vii. chloromethyl cyclobutanecarboxylate
        viii. chloromethyl 2-ethylhexanoate
        ix. chloromethyl 3-cyclopentylpropanoate
        x. chloromethyl cyclopropanecarboxylate
        xi. chloromethyl pentanoate
        xii. chloromethyl 2-methylpentanoate
        xiii. chloromethyl 3,5,5-trimethylhexanoate
        xiv. chloromethyl 2,2-dimethylbutanoate
        xv. chloromethyl 2-methylbutanoate
        xvi. chloromethyl hexanoate
        xvii. chloromethyl 2-ethylbutanoate
        xviii. chloromethyl butyrate
        xix. chloromethyl 3-phenylpropanoate
        xx. chloromethyl 2-phenylpropanoate
        xxi. (R)-chloromethyl 2-phenylpropanoate
        xxii. (S)-chloromethyl 2-phenylpropanoate
        xxiii. (1r,4r)-chloromethyl 4-methylcyclohexanecarboxylate
        xxiv. chloromethyl 4-methoxycyclohexanecarboxylate
        xxv. chloromethyl 4,4-difluorocyclohexanecarboxylate
        xxvi. chloromethyl 3-methoxycyclohexanecarboxylate
        xxvii. (2R)-chloromethyl 2-methylcyclopentanecarboxylate
        xxviii. (R)-chloromethyl 2-methylbutanoate
        xxix. (S)-chloromethyl 2-methylbutanoate
        xxx. (S)-chloromethyl 2-methoxy-2-phenylacetate
        xxxi. (S)-chloromethyl 2-phenylpropanoate
        xxxii. (S)-chloromethyl 2-phenylbutanoate
        xxxiii. (S)-chloromethyl 3-phenylbutanoate
        xxxiv. bis(chloromethyl) 2,2-dimethylmalonate
        xxxv. bis(chloromethyl) oxalate
        xxxvi. chloromethyl 2-cyclopropylacetate
        xxxvii. chloromethyl 2-cyclobutylacetate
        xxxviii. chloromethyl 2-cyclopentylacetate
        xxxix. chloromethyl 2-(tetrahydrofuran-3-yl)acetate
        xl. chloromethyl 2-(tetrahydro-2H-pyran-4-yl)acetate
        xli. chloromethyl 2-methylcyclopropanecarboxylate
        xlii. chloromethyl 2-(1-methylcyclobutyl)acetate
        xliii. chloromethyl 2-(1-methylcyclopropyl)'acetate
        xliv. chloromethyl propionate
        xlv. chloromethyl acetate
        xlvi. chloromethyl isobutyrate
        xlvii. chloromethyl 2-isopropyl-3-methylbutanoate
        xlviii. chloromethyl 3,5-dimethylcyclohexanecarboxylate
        xlix. chloromethyl 2-propylpentanoate
        l. chloromethyl 4-methoxybenzoate
        li. chloromethyl 4-methylbenzoate
        lii. chloromethyl 3-methylbenzoate
        liii. chloromethyl 2,2,2-trifluoroacetate
        liv. chloromethyl 5,5-dimethyl-3-oxohexanoate
        lv. bis(chloromethyl) cyclopropane-1,1-dicarboxylate
        lvi. chloromethyl 1,2-dihydrocyclobutabenzene-1-carboxylate
        lvii. chloromethyl 2-cyclopentenylacetate
        lviii. chloromethyl 2-phenylbutanoate
        lix. chloromethyl 2,2-difluoroacetate
        lx. chloromethyl 4-fluorobenzoate
        lxi. chloromethyl 3-cyclohexylpropanoate
        lxii. chloromethyl 2-cyclohexylacetate
        lxiii. chloromethyl 3-(tetrahydro-2H-pyran-4-yl)propanoate
        lxiv. chloromethyl 2-(tetrahydro-2H-pyran-3-yl)acetate
        lxv. chloromethyl 3-(tetrahydro-2H-pyran-3-yl)propanoate
        lxvi. chloromethyl nicotinate

Type III Reagents

        i. chloromethyl isopropylcarbamate
        ii. chloromethyl diisopropylcarbamate
        iii. chloromethyl dimethylcarbamate
        iv. chloromethyl isobutylcarbamate
        v. chloromethyl methylcarbamate
        vi. chloromethyl ethyl(isopropyl)carbamate
        vii. chloromethylisobutyl(methyl)carbamate
        viii. (S)-chloromethyl sec-butylcarbamate
        ix. chloromethyl methylcarbamate
        x. chloromethyl isopropyl(methyl)carbamate
        xi. chloromethyl propylcarbamate
        xii. chloromethyl 2-methoxyethylcarbamate
        xiii. chloromethyl methyl(propyl)carbamate
        xiv. chloromethyl diisobutylcarbamate
        xv. chloromethyl tert-butyl(isopropyl)carbamate
        xvi. chloromethyl di-sec-butylcarbamate
        xvii. chloromethyl aziridine-1-carboxylate
        xviii. chloromethyl 2-methylcyclopropylcarbamate
        xix. chloromethyl cyclopropylcarbamate
        xx. chloromethyl cyclopropylmethyl(propyl)carbamate
        xxi. chloromethyl cyclopropyl(methyl)carbamate
        xxii. chloromethyl azetidine-1-carboxylate
        xxiii. chloromethyl cyclobutylcarbamate
        xxiv. chloromethyl 2,2-dimethylcyclobutylcarbamate
        xxv. chloromethyl 3-methoxyazetidine-1-carboxylate
        xxvi. chloromethyl cyclobutyl(methyl)carbamate
        xxvii. chloromethyl oxetan-3-ylcarbamate
        xxviii. (S)-chloromethyl 2-methylpyrrolidine-1-carboxylate
        xxix. chloromethyl cyclopentylcarbamate
        xxx. chloromethl cyclopentyl(methyl)carbamate
        xxxi. chloromethyl tetrahydrofuran-3-ylcarbamate
        xxxii. chloromethyl piperidine-1-carboxylate
        xxxiii. (2R,6S)-chloromethyl 2,6-dimethylpiperidine-1-carboxylate
        xxxiv. (R)-chloromethyl 2-methylpiperidine-1-carboxylate
        xxxv. chloromethyl piperidine-1-carboxylate
        xxxvi. chloromethyl 3-methoxycyclohexylcarbamate
        xxxvii. chloromethyl cyclohexylmethylcarbamate
        xxxviii. chloromethyl cyclohexylmethyl(methyl)carbamate
        xxxix. chloromethyl morpholine-4-carboxylate
        xl. (3S,5R)-chloromethyl 3,5-dimethylmorpholine-4-carboxylate
        xli. (3R,5S)-chloromethyl 3,5-dimethylmorpholine-4-carboxylate
        xlii. (2S,6R)-chloromethyl 2,6-dimethylmorpholine-4-carboxylate
        xliii. chloromethyl 4-methylpiperazine-1-carboxylate
        xliv. chloromethylazepane-1-carboxylate
        xlv. chloromethylcycloheptylcarbamate
        xlvi. chloromethyl oxepan-4-ylcarbamate
        xlvii. chloromethyl (1R,2S,4S)-bicyclo[2.2.1]heptan-2-ylcarbamate
        xlviii. chloromethyl 2,3-dihydro-1H-inden-1-ylcarbamate
        xlix. chloromethyl benzylcarbamate
        l. (S)-chloromethyl 1-phenylethylcarbamate
        li. ethyl 2-((chloromethoxy)carbonylamino)-3-methylbutanoate
        lii. ethyl 2-((chloromethoxy)carbonylamino)-3-phenylpropanoate
        liii. (S)-diethyl 2-((chloromethoxy)carbonylamino)pentanedioate
        liv. ethyl((chloromethoxy)carbonylamino)propanoate
        lv. ethyl 2-amino-6-((chloromethoxy)carbonylamino)hexanoate
        lvi. ethyl 2-((chloromethoxy)carbonylamino)-4-methylpentanoate
        lvii. ethyl 2-((chloromethoxy)carbonylamino)-3-methylpentanoate
        lviii. (S)-dimethyl 2-((chloromethoxy)carbonylamino)succinate
        lix. (S)-ethyl 2-((chloromethoxy)carbonylamino)-5-guanidinopentanoate
        lx. (S)-ethyl 4-amino-2-((chloromethoxy)carbonylamino)-4-oxobutanoate
        lxi. (S)-ethyl 2-amino-5-((chloromethoxy)carbonylamino)pentanoate
        lxii. (S)-ethyl 5-amino-2-((chloromethoxy)carbonylamino)-5-oxopentanoate
        lxiii. ethyl 2-((chloromethoxy)carbonylamino)-4-(methylthio)butanoate
        lxiv. 1-chloromethyl 3-methyl 2-methyl-5,6-dihydropyridine-1,3(2H)-dicarboxylate
        lxv. (S)-chloromethyl (1-methylpyrrolidin-2-yl)methyl carbonate
        lxvi. (R)-chloromethyl (1-methylpyrrolidin-2-yl)methyl carbonate
        lxvii. (S)-(1-benzylpyrrolidin-2-yl)methyl chloromethyl carbonate
        lxviii. chloromethyl 1H-pyrrole-1-carboxylate
        lxix. chloromethyl 2-nicotinoylhydrazinecarboxylate
        lxx. (6S)-3-chloro-7-((chloromethoxy)carbonylamino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
        lxxi. (6S)-7-((chloromethoxy)carbonylamino)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
        lxxii. (6S)-7-((chloromethoxy)carbonylamino)-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
        lxxiii. (6R,7R)-7-((chloromethoxy)carbonylamino)-3-methoxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
        lxxiv. chloromethyl 3-(4-chlorophenyl)-1H-pyrazole-1-carboxylate
        lxxv. chloromethyl 3-(4-fluorophenyl)-1H-pyrazole-1-carboxylate
        lxxvi. chloromethyl 3-phenyl-1H-pyrazole-1-carboxylate
        lxxvii. chloromethyl 3-(4bromophenyl)-1H-pyrazole-1-carboxylate
        lxxviii. chloromethyl 2-cyano-1H-pyrrole-1-carboxylate
        lxxix. chloromethyl 4-oxopiperidine-1-carboxylate
        lxxx. 1-chloromethyl 3-ethyl 2-oxopiperidine-1,3-dicarboxylate
        lxxxi. chloromethyl 2,2,6,6-tetramethyl-4-oxopiperidine-1-carboxylate
        lxxxii. chloromethyl 2-oxopiperidine-1-carboxylate
    
    


The novel compounds of the present application include compounds of Formula (III) and Formula (IV):




Where A or B=











where R5 represents a nitrogen atom of the imatinib moiety linked to A or B, and

X may be iodide, chloride, bromide, mesylate, tosylate, or any other pharmaceutically acceptable anion to provide a pharmaceutically acceptable salt.

The compounds generated may be present as a single stereoisomer (e.g., enriched to at least 95% purity relative to the total amount of all stereoisomers present), a racemate, or a mixture of enantiomers or diastereomers in any ratio.
The novel compounds herein may be any of the compounds as below:




1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-((pivaloyloxy)methyl)piperazin-1-ium iodide




1-methyl-4-(4-((4-methyl-3-((4-(1-((pivaloyloxy)methyl)pyridin-1-ium-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-((pivaloyloxy)methyl)piperazin-1-ium diiodide




1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-(((morpholine-4-carbonyl)oxy)methyl)piperazin-1-ium iodide




1-(((isopropoxycarbonyl)oxy)methyl)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium iodide




1-(((isopropoxycarbonyl)oxy)methyl)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium methane sulfonate




1-(((isopropoxycarbonyl)oxy)methyl)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium p-tolyl sulfonate




1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)-1((3-methylbutanoyloxy)methyl)piperazin-1-ium iodide




1-((isopropylcarbamoyloxy)methyl)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide




(R)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)-1-(((1-phenylethoxy)carbonyloxy)methyl)piperazin-1-ium iodide




(R)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)-1-((1-phenylethylcarbamoyloxy)methyl)piperazin-1-ium iodide




(R)-1-((sec-butoxycarbonyloxy)methyl)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide




1-(isobutyryloxymethyl)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide




1-((benzyloxycarbonyloxy)methyl)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide




(R)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)-1-(((1-phenylethoxy)carbonyloxy)methyl)piperazin-1-ium iodide




1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)-1-(((3-methylbutan-2-yloxy)carbonyloxy)methyl)piperazin-1-ium iodide




1-((benzyl(methyl)carbamoyloxy)methyl)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide




(S)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)-1-((1-phenylethylcarbamoyloxy)methyl)piperazin-1-ium iodide




1-((ethoxycarbonyloxy)methyl)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide




1-((cyclobutoxycarbonyloxy)methyl)-1-methyl-4-(4-(3-methyl-4-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide




1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium methanesulfonate




1-2,2-dimethylbutanoyloxy)methyl)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide




1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)-1-((tert-pentyloxycarbonyloxy)methyl)piperazin-1-ium iodide




(R)-1-((sec-butylcarbamoyloxy)methyl)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide




1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)-1-((2-phenylacetoxy)methyl)piperazin-1-ium iodide




4-(4-((3-((4-(1-(((isopropoxycarbonyl)oxy)methyl)pyridin-1-ium-3-yl)pyrimidin-2-yl)amino)-4-methylphenyl)carbamoyl)benzyl)-1-methylpiperazin-1-ium
4-(4-((3-((4-(1-(((isopropoxycarbonyl)oxy)methyl)pyridin-1-ium-3-yl)pyrimidin-2-yl)amino)-4-methylphenyl)carbamoyl)benzyl)-1-methylpiperazin-1-ium monoiodide monomesylate




3-(2-((2-methyl-5-(4-((4-methylpiperazin-1-yl) methyl) benzamido)phenyl)amino)pyrimidin-4-yl)-1-(((morpholine-4-carbonyl)oxy)methyl)pyridin-1-ium monoiodide monomesylate










TABLE 1





No.
Structure
IUPAC name
m/z







 1030




1-methyl-4-(4- ((4-methyl-3- ((4-(pyridin-3- yl)pyrimidin-2- yl)amino)phenyl) carbamoyl) benzyl)-1-((2- phenylacetoxy) methyl)piperazin- 1-ium iodide
643


 


10737.02




1-methyl-4-(4- ((4-methyl-3- ((4-(pyridin-3- yl)pyrimidin-2- yl)amino)phenyl) carbamoyl) benzyl)-1-((2- phenylacetoxy) methyl)piperazin- 1-ium methane- sulfonate
643


 


10737.04




1-methyl-4-(4- ((4-methyl-3- ((4-(pyridin-3- yl)pyrimidin-2- yl)amino)phenyl) carbamoyl) benzyl)-1-((2- phenylacetoxy) methyl)piperazin- 1-ium tetrafluoro- borate
643


 


10737.06




1-methyl-4-(4- ((4-methyl-3- ((4-(pyridin-3- yl)pyrimidin-2- yl)amino)phenyl) carbamoyl) benzyl)-1-((2- phenylacetoxy) methyl)piperazin- 1-ium trifluoro- methanesulfonate
643


 


10737.07




1-methyl-4-(4- ((4-methyl-3- ((4-(pyridin-3- yl)pyrimidin-2- yl)amino)phenyl) carbamoyl) benzyl)-1-((2- phenylacetoxy) methyl)piperazin- 1-ium nitrate
643


 


10737.08




1-methyl-4-(4- ((4-methyl-3- ((4-(pyridin-3- yl)pyrimidin-2- yl)amino)phenyl) carbamoyl) benzyl)-1-((2- phenylacetoxy) methyl)piperazin- 1-ium p-toluene sulfonate
643


 


11124.01




1-methyl-4-(4- ((4-methyl-3- ((4-(pyridin-3- yl)pyrimidin-2- yl)amino)phenyl) carbamoyl) benzyl)-1-(((2- phenylpropanoyl) oxy)methyl) piperazin-1-ium  iodide
657


 


11124.02




1-methyl-4-(4- ((4-methyl-3- ((4-(pyridin-3- yl)pyrimidin-2- yl)amino)phenyl) carbamoyl) benzyl)-1-(((2- phenylpropanoyl) oxy)methyl) piperazin-1-ium  tetrafluoroborate
657


 


11124.03




1-methyl-4-(4- ((4-methyl-3- ((4-(pyridin-3- yl)pyrimidin-2- yl)amino)phenyl) carbamoyl) benzyl)-1-(((2- phenylpropanoyl) oxy)methyl) piperazin-1-ium  methanesulfonate
657









A. Synthesis of the Compounds of the Present Invention
The present invention also relates to a process of synthesis of the compounds of the present invention;
The synthesis of the compounds of the present invention may be as enumerated below:




Step 1:—

Imatinib (1001) when reacted with a suitable halomethyl reagent (Type I or II or III) [1a] in a solvent such as DCM at a temperature ranging from room temperature to refluxing followed by evaporation of excess of solvent yield final product [1] which may be further purified to desire level either by crystallization of by washing with a solvent such as ether.
Step 2:—General Scheme for Counter Ion Exchange:




A quaternary salt such as [2] may be prepared by the method describe above in step 1 with a suitable halomethyl formyl reagent such as iodo methyl formyl (Type I or Type II or Type III). Compound [2] may be treated with a suitable metal salt such as silver mesylate in a suitable solvent such as acetonitrile at a desired temperature ranging from ambient to refluxing which results in the precipitation of silver iodide and formation of desired product [3]. The insoluble silver halide maybe filtered out to get reasonably pure desire product [3].




Imatinib mesyalte, 1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium methanesulfonate [1026] reacted with suitable halomethyl reagent (Type I or II or III) [1a] in dry solvent such as acetonitrile and at a temperature ranging from room temperature to refluxing followed by evaporation of excess of solvent yield final product [4] which if required can be purified further either by crystallization or by solvent washing with a solvent such as ether.
The above methods are applicable to do anion exchange on all type of quaternary salts having any halide such as chloride, bromide or iodide as the counter ion. The non limiting list of silver salts that may be use includes silver acetate, silver mesylate, silver tosylate, silver oxalate, silver tartrate, silver triflate etc.
The compounds of formula II may be divided in three classes i.e. Type I, where Y═OR2; Type II, where Y═R2 and Type III, where Y═NR2R3 and may be synthesized by the general schemes as below.
General Methods for the Preparation of Formula II:
The compounds of formula II (Type I, II, III) may be prepared from respective acids, amines and alcohols directly. An acid with or without activation may be reacted with a corresponding aldehyde in presence of a Lewis acid may provide Type II reagent. An alcohol may be reacted with a halomethylhaloformate in presence of a base to provide Type I reagent. Similarly, an amine (primary or secondary) may be reacted with halomethyl haloacetate with or without the presence of base may provide Type III reagent.
General Method to Synthesize Type II Reagents




Lewis acids such as zinc chloride (dry), aldehydes such as paraformaldehyde and acid chlorides, [5], may be reacted under anhydrous conditions and at appropriate temperatures, typically between −10° C. and 60° C. for a time ranging up to 24 hours. The reaction mixture may be diluted with solvents such as dichloromethane, washed with aqueous dilute base such as a solution of Na2HCO3. Standard work up and purifications yield the desired Reagents, [6].




Metal salt of desired acid such as caesium salt of Acid [4], may be treated with bromoiodomethane in Dry THF at appropriate temperatures, typically between 0° C. to RT for 16 hours and if required heating. The reaction mixture may be diluted with solvents such as ethyl acetate, washed with aqueous dilute base such as aqueous solution of Na2HCO3. Standard work up and purifications yield the desired Reagents [7].




To a vigorously stirred, solution of acid [4] in a solvent such as dichloromethane at room temperature, a base such as sodium bicarbonate and tetrabutylammonium bisulfate in water was added, followed by the drop-wise addition of a solution of chloromethyl chlorosulfate in a solvent such as dichloromethane. After completion of reaction, organic layer was washed with 5% aqueous Na2CO3. Standard work up and purifications yields desired reagents, [6].
1.
General Method to Synthesize Type III Reagents




Corresponding primary or secondary amines may be reacted with substituted or unsubstituted chloro methylchloroformate, [8], in a solvent such as hexane or DCM at 0° C. The reaction mixture may be filtered and the filtrate may be washed with 1.0 N HCl. The organics may be evaporated to get the desired reagent, [9]. If required, further purification may be achieved using any general purification method practiced in organic chemistry laboratory such as precipitation or crystallization or preparative column purification.
As illustrated above, R and R1 are each independently selected from H, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, C1-C8 alkyl and C3-C7 cycloalkyl, wherein in each of the C1-C8 alkyl and C3-C7 cycloalkyl optionally up to three carbon atoms are replaced by a heteroatom group independently selected from O, NR4, S, SO and SO2 (i.e., thereby making a heteroalkyl or heterocyclyl substituent), and wherein the C1-C8 alkyl and C3-C7 cycloalkyl are optionally substituted with from 1 to 4 C1-C8 alkyl, alkoxy, aryl and heteroaryl substituents; or R and R1 taken together with the atom to which they are attached form a 3- to 7-membered ring, wherein the 3- to 7-membered ring optionally contains up to two heteroatom groups selected from O, N R4, S, SO and SO2, and is optionally substituted with 1 to 4 alkoxy, F or Cl substituents;

    
    
        Y is selected from R2, OR2, NH2, NHR2, and NR2R3;
        R2 is selected from alkoxy, aryl, heteroaryl, C1-C8 alkyl and C3-C7 cycloalkyl, wherein in each of said C1-C8 alkyl and C3-C7 cycloalkyl optionally up to three carbon atoms are replaced by a heteroatom group independently selected from O, NR4, S, SO and SO2 (i.e., thereby making a heteroalkyl or heterocyclyl substituent), and wherein the C1-C8 alkyl and C3-C7 cycloalkyl are each optionally substituted with from 1 to 4 C1-C8 alkyl, alkoxy, aryl or heteroaryl substituents;
        R3 is selected from alkoxy, aryl, heteroaryl, C1-C8 alkyl and C3-C7 cycloalkyl, wherein in each of the C1-C8 alkyl and C3-C7 cycloalkyl optionally up to three carbon atoms are replaced by a heteroatom group independently selected from O, NR4, S, SO and SO2 (i.e., thereby making a heteroalkyl or heterocyclyl substituent), and wherein the C1-C8 alkyl and C3-C7 cycloalkyl are each optionally substituted with from 1 to 4 C1-C8 alkyl, alkoxy, aryl or heteroaryl; or
        R2 and R3 may be taken together with the nitrogen atom to which they are attached to form a 3- to 7-membered ring, wherein the 3- to 7-membered ring optionally contains up to three heteroatom groups selected from O, NR4, S, SO and SO2, and is optionally substituted with alkoxy, F or Cl.

General Method to Synthesize Type I Reagents

    
    






To the solution of chloromethylchloroformate, [10], in a solvent such as hexane, may be added solution of pyridine in hexane, drop wise under ice cooling. To this reaction mixture, the corresponding alcohol may be added at the same temperature. The reaction mixture may be stirred for a time ranging up to 24 hrs. Standard work up and purifications yield the desired corresponding carbonate reagent, [11].
As illustrated above, R2 is selected from alkoxy, aryl, heteroaryl, C1-C8 alkyl and C3-C7 cycloalkyl, wherein in each of said C1-C8 alkyl and C3-C7 cycloalkyl optionally up to three carbon atoms are replaced by a heteroatom group independently selected from O, NR4, S, SO and SO2 (i.e., thereby making a heteroalkyl or heterocyclyl substituent), and wherein the C1-C8 alkyl and C3-C7 cycloalkyl are each optionally substituted with from 1 to 4 C1-C8 alkyl, alkoxy, aryl or heteroaryl substituents.




Reagents [6] when treated with bromide suitable reagent such as lithium bromide or sodium bromide at appropriate temperatures, typically in the range of 40-80° C. for a time ranging up to 24 hours followed by standard work up and purification, yields desired bromo Reagents, [7].




Reagents [6] when treated with a reagent such as sodium iodide at appropriate temperatures, typically ranging from room temperature to 60° C. for a time ranging up to 24 hours followed by a standard work up and purification, yields desired iodo Reagents, [12].




Reagents [6] when treated with silver salt of methane sulfonic acid at appropriate temperatures, typically ranging from room temperature to 60° C. to 90° C. for a time ranging up to 24 hours followed by standard work up and purification, yield desired ((methylsulfonyl)oxy) Reagents, [14].




Reagents [6] when treated with silver salt of p-methyl benzene sulfonic acid at appropriate temperatures, typically ranging from room temperature to 60° C. to 90° C. for a time ranging up to 24 hours followed by standard work up and purification yield the desired ((methylsulfonyl)oxy) Reagents, [14].
B. Composition of the Compounds of the Present Invention
The present invention further provides pharmaceutical compositions comprising a compound of formula (I) or its pharmaceutically acceptable salt thereof as an active ingredient along with pharmaceutically acceptable additives/excipients/adjuvants/vehicles. The composition may be administered in a variety of ways including orally, nasally, buccally, sublingually, intravenously, transmucosally, parenterally, by inhalation, spray, transdermally, subcutaneously, intrathecally topically or rectally and may be formulated according to methods known in the art.
The effective dosage form for a mammal may be about 0.1-100 mg/kg of body weight of active compound, which may be administered as a single dose or in the form of individual doses, such as from 1 to 4 times a day.
The mammal may be an adult human.
The compounds of the present invention may optionally be administered with one or more additional drugs. Exemplary additional drugs include one or more compounds independently selected from the group comprising central nervous system drugs, such as cns/respiratory stimulants, analgesics, narcotic agonists, narcotic agonist/antagonists, nonsteroidal anti-inflammatory/analgesic agents, behavior-modifying agents, tranquilizers/sedatives, anesthetic agents, inhalants, narcotics, reversal agents, anticonvulsants, muscle relaxants, skeletal, muscle relaxants, smooth, euthanasia agent, cardiovascular agents, inotropic agents, antiarrhythmic drugs, anticholinergics, vasodilating agents, agents used in treatment of shock, alpha-adrenergic blocking agents, beta-adrenergic blocking agents, respiratory drugs, bronchodilators, sympathomimetics, antihistamines, antitussives, renal and urinary tract, agents for urinary incontinence/retention, urinary alkalinizers, urinary acidifiers, cholinergic stimulants, agents for urolithiasis, gastrointestinal agents, antiemetic agents, antacids, h2 antagonists, gastromucosal protectants, proton pump inhibitors, appetite stimulants, gi antispasmodics-anticholinergics, gastro intestinal stimulants, laxatives, saline, bulk producing, lubricant, surfactant, antidiarrheals, hormones/endocrine/reproductive agents, sex hormones, anabolic steroids, posterior pituitary hormones, adrenal cortical steroids, glucocorticoids, antidiabetic agents, thyroid drugs, thyroid hormones, misc. endocrine/reproductive drugs, prostaglandins, antiinfective drugs, antiparasitics, anticoccidial agents, antibiotics, anti-tuberculosis, aminocyclitols, cephalosporins, macrolides, penicillins, tetracyclines, lincosamides, quinolones, sulfonamides, miscellaneous antibacterials, antifungal agents, antiviral agents, blood modifying agents, clotting agents, anticoagulants, erythropoietic agents, antineoplastics/immunosuppresives, alkylating agents, antidotes, bone/joint agents, dermatologic agents (systemic), vitamins and minerals/nutrients, systemic acidifiers, systemic alkalinizers, anti-cancer agents, anti-viral agents, etc.
C. Methods of Use
The present invention further provides a method of prophylaxis and/or treatment of, and/or ameliorating the symptoms of diseases comprising administering a therapeutically effective amount of a compound of formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the compound of formula (I) as the active ingredient.
The compounds of the present invention are useful as c-ABL1 inhibitors and are useful in all disorders where alteration of the amount of c-ABL1 is required in mammals, including humans. The compounds of the present invention may also act as PGDFR inhibitors in mammals, including humans. The compounds of the present invention may also act as inhibitors of stem cell factor receptor (SCFR), also known as c-Kit, in mammals, including humans.
The compounds of the present invention may be used to treat mammals including humans, suffering from a tumoral disease a dose, effective against tumours.
Imatinib mesylate (Gleevec) has been shown to be effective against poxvirus infections by disabling host proteins essential to the virus life cycle (Nature Medicine, 2005, vol. 11, 7, page 731-739) and without interfering with the acquisition of immune memory (Journal of Virology, 2011, vol. 85, 1, p. 21-31).
Similarly, by targeting the host gene products rather the virus itself, short-term administration of imatinib mesylate may be useful in treating Ebola virus infections (Science Translational Medicine, 2012, vol. 4, 123, page 1-10).
Furthermore, Ab1 family kinases have been shown to regulate the susceptibility of cells to polyomavirus infection by modulating gangliosides required for viral attachment (Journal of Virology, 2010, vol. 84, 9, p. 4243-4251). Hence, Ab1 kinase inhibitor, e.g., imatinib mesylate may prove useful as therapeutics of human polyomaviruses.
The present application provides a method for preventing or treating a bacterial infection or a viral infection in a subject using a novel compounds as described herein.
In certain embodiments, the bacterial infection is caused by Pseudomonas aeruginosa, Chlamydia trochomatis, Escherichia coli, Helicobacter pylori, Listeria monocytogenes, Salmonella typhimurium, Shigella flexneri, or Mycobacterium tuberculosis. 
In certain embodiments, Mycobacterium tuberculosis causes MDR-tuberculosis or XDR-tuberculosis.
In certain embodiments, the viral infection is caused by a Vaccinia virus, a variola virus, a polyoma virus, a Pox virus, a Herpes virus, a cytomegalovirus (CMV), a human 5 immunodeficiency virus, JC virus, BK virus, Simian virus 40 (SV 40), Monkeypox virus, Ebola virus, Marburg virus, Bunyavirus, Arenavirus, Alphavirus e.g., Venezualan equine encephalitis (VEE), Western equine encephalitis (WEE), Flavivirus, West Nile virus or SARS Coronavirus.
In some embodiments, the compounds described in the present application have improved/maintain desirable safety and toxicity profile relative to imatinib mesylate.
In some embodiments, the compounds described in the present application are more soluble than imatinib mesylate in saline and/or at biologically useful pH ranges.
In some embodiments, the compounds described in the present application have modified rate of conversion and thereby may cause a change in the dosage and/or dosing regimen relative to imatinib mesylate.
In some embodiments, the compounds described in the present application may be such that they are cleaved in certain therapeutically important location(s), thereby enabling specificity and selectivity and or targeted drug delivery.
All of the U.S. Patents and other publications cited herein are expressly incorporated by reference herein in each of their entireties.
From the foregoing description, one of ordinary skill in the art can easily ascertain the essential characteristics of the instant invention, and without departing from the spirit and scope thereof can make various changes and/or modifications of the invention to adapt it to various usages and conditions. Accordingly, these changes and/or modifications are properly, equitably and intended to be, within the full range of equivalence of the claims that follow.
EXAMPLES
Example 1: Synthetic Procedure for the Synthesis an Exemplary Type III Reagent




Step (A):

To the solution of chloromethylchloroformate [10] (1.0 g, 7.75 mmol, 1.0 eq) in DCM (y ml) was added a solution of isopropyl amine (0.95 g, 19.30 mmol, 2.5 eq) in DCM drop wise at 0° C. White solid precipitated out in the reaction mixture on addition. The resulting mixture was stirred for 2 hours at 0° C. and then at RT for 1 hour. Reaction was monitored by TLC. The reaction was worked up by diluting the reaction mixture with DCM, washing with saturated NaHCO3 solution, followed by a wash with 2N HCl solution, again washing with saturated NaHCO3 solution, and lastly with water. The organic layer was separated, dried over Na2SO4 and evaporated under reduced pressure to give chloromethyl isopropylcarbamate [15] as colorless oil (0.50 g, 44%).
1H NMR [CDCl3, 300 MHz]: δ 5.73 (s, 2H), 4.73 (s, —NH), 3.78-3.91 (m, 1H), 1.17-1.19 (d, 6H)
Step (B):
Sodium iodide (0.6 g, 3.99 mmol, 3.0 eq) was added to a solution of chloromethyl isopropylcarbamate [15] (0.2 g, 1.33 mmol, 1.0 eq) in acetone. The resulting reaction mixture was stirred at RT overnight. Reaction was monitored by TLC. The reaction was worked up by filtering out precipitated solid and evaporating the acetone layer under vacuum. The solid obtained was dissolved in DCM and filtered to get rid of residual solid. The DCM layer thus obtained was evaporated under reduced pressure to get a crude product, which was purified using silica gel column chromatography (2% MeOH: DCM, 100-200 mesh yield pure iodomethyl isopropylcarbamate [16] as colorless sticky material (0.12 g, 37%). 1H NMR [CDCl3, 300 MHz]: δ 5.96 (s, 2H), 4.65 (s, —NH), 3.80-3.91 (m, 1H), 1.17-1.19 (d, 6H).
Example 2




Chloromethyl morpholine-4-carboxylate [17] (0.3 g, 1.67 mmol, 1.0 eq) and sodium bromide (0.86 g, 8.3 mmol, 5.0 eq) was taken in acetone (10 ml). The reaction was refluxed at 60° C. for 24 h. Reaction progress was monitored by TLC/1H NMR. The reaction was filtered off and filtrate was evaporated to dryness under reduced pressure to yield light brown gel, bromomethyl morpholine-4-carboxylate [18] (0.30 g, 80%)
1H NMR (CDCl3): δ ppm 5.92 (s, 2H), 3.72 (t, 4H), 3.54 δ(t, 4H) s
Example 3




Procedure:

Chloromethyl morpholine-4-carboxylate [19] (0.3 g, 1.67 mmol, 1.0 eq) and lithium bromide (0.72 g, 8.3 mmol, 5.0 eq) was taken in acetonitrile (10 ml). The reaction was refluxed at 90° C. for 30 h. Reaction progress was monitored by TLC/1H NMR. The reaction was filtered off and filtrate was evaporated to dryness under reduced pressure to yield light brown gel, bromomethyl morpholine-4-carboxylate [20] (0.30 g, 80%)
1H NMR (CDCl3): δ ppm 5.92 (s, 2H), 3.72 (t, 4H), 3.54 (t, 4H)
Other methyl formyl reagents were synthesized using the synthetic procedures disclosed above and herein with various substituted or unsubstituted alcohols, phenols, amines and acids to get various structures.
Example 4: Example of a Typical Synthetic Procedure for the Synthesis of Type I Reagents




Procedures:

Step (A):

To a solution of chloromethylchloroformate [10] (7.75 mmol, 1 eq) in hexane was added a solution of pyridine (19.3 mmol, 2.5 eq) in hexane drop wise under ice cooling. After the complete addition, a white solid precipitate formed. t-Butanol (11.62 mmol, 1.5 eq) was added in hexane at the same temperature. After the addition of t-butanol the reaction mixture became a clear solution. The resulting mixture was stirred for 2 hours under ice cooling and then 1 hour at room temperature (RT). Reaction completion was monitored by TLC, which showed one non-polar spot compared to starting material. The reaction was worked up by diluting the reaction mixture with hexane and washing with saturated NaHCO3 solution, followed by 2N HCl solution, followed by a second washing with saturated NaHCO3 solution, and lastly by water. The organic layer was separated, dried over Na2SO4 and evaporated under reduced pressure to give the reagent tert-butyl (chloromethyl) carbonate [21] as a colorless sticky liquid (0.900 g, 70%).
1H NMR: [CDCl3, 300 MHz]: −δ 5.774 (s, 2H), 1.518 (s, 9H).
Step (B):
To a solution of tert-butyl (chloromethyl) carbonate [21] (9.87 mmol, 1 eq) dissolved in acetone was added sodium iodide (29.61 mmol, 3 eq). The resulting reaction mixture was stirred overnight at RT. The TLC showed consumption of starting material and one new non polar spot compared to starting material. The reaction was worked up by filtering out any precipitated solid and evaporating the acetone layer. The solid obtained was dissolved in DCM. The solution was filtered once again to eliminate any solid not dissolved in the DCM. The DCM layer obtained was evaporated. The crude product was passed through column chromatography by using 100-200 mesh size silica and 1% MeOH-DCM as a solvent system to yield the product tert-butyl (iodomethyl) carbonate [22] as colorless liquid (136 mg, 30%).
1H NMR [CDCl3, 300 MHz]: δ 5.90 (s, 2H), 1.518 (s, 9H).
Example 5: Synthetic Procedure for an Exemplary Type II Reagent




Step (A):

An appropriate Lewis acid such as zinc chloride (catalytic amount −0.50 g) was fused in a dried 2-neck round bottomed flask under inert atmosphere. Iso-butyryl chloride [23] (46.72 mmol, 1 eq) and paraformaldehyde (47.0 mmol, 10 eq) are added to the prepared Lewis Acid at RT. The reaction mixture was heated to 60° C. overnight. The reaction was monitored by TLC. The reaction was stopped by addition of DCM and washed with saturated NaHCO3 then brine. The organic layer was separated, dried over Na2SO4 and evaporated under reduced pressure to yield the product, chloromethyl isobutyrate [24], as colorless oil (2.0 g, 31%).
1H NMR [CDCl3, 300 MHz]: δ 5.71-5.76 (d, 2H), 2.54-2.64 (m, 1H), 1.17-1.21 (d, 6H)
Step (B):
Sodium iodide (43.9 mmol, 3 eq) was added to a solution of chloromethyl isobutyrate [24] (14.6 mmol, 1 eq) in acetone. The resulting reaction mixture was stirred at RT overnight. Reaction completion was monitored by TLC. The reaction was worked up by filtering out precipitated solid and evaporation of excess of acetone under reduced pressure. A solid was obtained and washed with DCM while filtering under suction using a Buchner funnel. The DCM layer obtained was evaporated to provide crude product which was further purified using silica gel column chromatography (100-200 mesh) and DCM as an eluent. The product, iodomethyl isobutyrate [25], (1.6 g, 50% yield) was obtained as a brownish liquid.
1H NMR [CDCl3, 300 MHz]: δ 6.21 (s, 2H), 2.54-2.64 (m, 1H), 1.17-1.21 (d, 6H).
Example 6: Synthesis of ((Methylsulfonyl)Oxy)Methyl 3-Methylbutanoate




Procedure:

Silver salt of methane sulfonic acid [0.34 g, 1.6 mmol, 0.5 eq] was taken in acetonitrile (8 ml) and chloromethyl 3-methylbutanoate [26] (0.5 g, 3.3 mmol, 1.0 eq) was added to it. The resulting solution was heated to 60° C. temperature ranging from 30 to 80° C., preferably 60° C. for 1 to 10 hour, preferably 5 hour for 5 h. Reaction progress was monitored by TLC. After completion, the reaction was filtered and solvent was evaporated under vacuum to yield colorless oil. The crude compound was purified by silica gel column chromatography (10% EtOAc: CyHex, 100-200 mesh) which afforded [27] ((methylsulfonyl)oxy)methyl 3-methylbutanoate [0.25 g, 40%] as a colorless oil.
Example 6a
Synthesis of ((Methylsulfonyl)Oxy)Methyl 3-Methylbutanoate




Procedure:

Silver salt of para-toluene sulfonic acid [0.3 g, 1.0 mmol, 0.5 eq] was taken in acetonitrile (8 ml) and chloromethyl 3-methylbutanoate [26] (0.48 g, 3.0 mmol, 1.0 eq) was added to it. The resulting solution was heated to 60° C. temperature ranging from 30 to 80° C., preferably 60° C. for 1 to 10 hour, preferably 5 hour for 5 h. Reaction progress was monitored by TLC. After completion, the reaction was filtered and solvent was evaporated under vacuum to yield colorless oil. The crude compound was purified by silica gel column chromatography (10% EtOAc: CyHex, 100-200 mesh) which afforded [28] ((methylsulfonyl)oxy)methyl 3-methylbutanoate [0.26 g, 35%] as a colorless oil.
Synthesis of Modified Forms of Imatinib
Example 6b




Imatinib, N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide, [1001] (0.100 g, 0.2 mmol, 1.0 eq) was dissolved in dichloromethane (10 ml) in a 25 ml two-necked round-bottomed flask, and iodomethyl pivalate [29] (0.049 g, 0.2 mmol, 1.0 eq) was added at RT. After stirring for 3-4 hours, the precipitate formed was filtered and washed with DCM to give the product, 1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-((pivaloyloxy)methyl)piperazin-1-ium iodide, [1002] as a yellow solid (0.04 g, 27%).
m/z: 608.
1H NMR [DMSO, 300 MHz]: δ ppm 1.24 (s, 9H), 2.20 (s, 3H), 2.7 (m, 4H), 3.10 (s, 3H), 3.07 (s, 3H), 3.48 (br s, 4H), 3.71 (s, 2H), 5.39 (s, 2H), 7.19 (d, 1H), 7.42-7.54 (m, 5H), 7.9 (d, 2H), 8.06 (d, 1H), 8.45-8.52 (m, 2H), 8.60 (dd, 1H), 9.0 (s, 1H), 9.27 (d, 1H), 10.18 (s, 1H)
Example 7




Imatinib [1001] (0.10 g, 0.2 mmol, 1.0 eq) was dissolved in DCM (10 ml) in a 25 ml two-necked round-bottomed flask and iodomethyl pivalate [29] (0.185 g, 0.77 mmol, 3.8 eq) was added while stirring at RT. After 48 h stirring, the precipitate formed was filtered under vacuum and washed with DCM to give the product, 1-methyl-4-(4-((4-methyl-3-((4-(1-((pivaloyloxy)methyl)pyridin-1-ium-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-((pivaloyloxy)methyl)piperazin-1-ium diiodide [1003], as a yellow solid (0.05 g, 25%). m/z: 361.
Example 8




Imatinib, N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide, [1001] (0.100 g, 0.2 mmol, 1.0 eq) was dissolved in dichloromethane (10 ml) in a 25 ml two-necked round-bottomed flask, and iodomethyl carbamate [30] (0.055 g, 0.2 mmol, 1.0 eq) in dichloromethane (5 ml) was added at RT. After stirring for 3-4 hours, the precipitate formed was filtered and washed with DCM to give the product, 1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-(((morpholine-4-carbonyl)oxy)methyl)piperazin-1-ium iodide, [1004] as a yellow solid (0.060 g, 50%). m/z: 637
Example 9




Imatinib, N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide, [1001] (0.100 g, 0.2 mmol, 1.0 eq) was dissolved in dichloromethane (10 ml) in a 25 ml two-necked round-bottomed flask, and iodomethyl isopropyl carbonate [31] (0.047 g, 0.2 mmol, 1.0 eq) in dichloromethane (5 ml) was added at RT. After stirring for 3-4 hours, the precipitate formed was filtered and washed with DCM to give the product, 1-(((isopropoxycarbonyl)oxy)methyl)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium iodide, [1005] as a yellow solid (0.035 g, 40%). m/z: 610
Example 10




To a suspension of Imatinib, N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide, [1001] (0.100 g, 0.2 mmol, 1.0 eq) in acetonitrile (10 ml) in a 25 ml two-necked round-bottomed flask, and ((isopropoxycarbonyl)oxy)methyl methanesulfonate [32] (0.043 g, 0.2 mmol, 1.0 eq) in acetonitrile (5 ml) was added at RT. The resulting suspension was heated at 80° C. for 24 hrs, The progress of the reaction was monitored by TLC. Then it was cooled to room temperature and evapourated to dryness. The resulting residue was redissolved in dichloromethane (1 ml) and reprecipitated by adding n-pentane, precipitate was filtered and dried to yield crude product, 1-(((isopropoxycarbonyl)oxy)methyl)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium iodide, [1006] as a yellow solid (0.034 g, 27%). The characterization was done by Mass spectroscopy. m/z: 610
Example 11a




To a stirred solution of (1-(((isopropoxycarbonyl)oxy)methyl)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium) iodide [1005] (0.0163 g, 0.027 mmol, 1.0 eq) in ACN (2 ml) was added silver(I) methanesulfonate (0.0054 g, 0.027 mmol, 1.0 eq) at RT. The reaction mixture was stirred at RT for 2 h. The reaction was filtered to get rid of silver iodide. Filtrate was concentrated under vacuum, which was triturated with dry ether (2×5 ml), ether removed by decantation and product dried under vacuum to get a pale yellow solid 1-(((isopropoxycarbonyl)oxy)methyl)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium methane sulfonate [1006] (0.012 g, 66%). m/z: 610
Example 11b




Imatinib [1001] (0.100 g, 0.2 mmol, 1.0 eq) was dissolved in dichloromethane (10 ml) in a 25 ml two-necked RBF followed by addition of iodomethyl 3-methylbutanoate [200] (0.049 g, 0.2 mmol, 1.0 eq) at RT. Reaction mixture was stirred for 4-5 hours, the yellow precipitate thus formed was filtered and washed with DCM to give the product, 1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-(((3-methylbutanoyl)oxy)methyl)piperazin-1-ium iodide [1008] as a yellow solid (0.080 g, 55%). m/z: 608.
Example 12




Imatinib mesyalte, 1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium methanesulfonate [1026] (0.100 g, 0.169 mmol, 1.0 eq) was taken in dry acetonitrile (6 ml) in a flame dried 2 neck RB flask equipped with refluxing condenser. To this suspension iodomethyl isopropyl carbonate [31] (0.041 g, 0.169 mmol, 1 eq) was added and heated the reaction mixture at 60° C. for 16 Hrs. During the reaction progress the suspension was turned into a light yellow clear solution. The progress of the reaction was monitored by TLC and 1H NMR. After 16 Hrs the solvent was evaporated to dryness and washed the resulting crude reaction mass with diethyl ether (10 ml×2) to give the product, 11-(((isopropoxycarbonyl)oxy)methyl)-3-(2-((2-methyl-5-(4-((4-methylpiperazin-1-yl)methyl)benzamido)phenyl)amino)pyrimidin-4-yl)pyridin-1-iummonoiodide monomethanesulfonate, [1031] as a brown gel (0.105 g, 74%). m/z: 611.
1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-(((3-methylbutanoyl)oxy)methyl)piperazin-1-ium iodide, [1008] was synthesized using (procedure similar to that used for the synthesis of [1002]) using [1001]), iodomethyl 3-methylbutanoate [200] and DCM as solvent.




1-(((isopropylcarbamoyl)oxy)methyl)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium iodide [1009] was synthesized using (procedure similar to that used for the synthesis of [1002] using [1001]), iodomethyl isopropylcarbamate [16] and DCM as solvent.




(R)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-((((1-phenylethoxy)carbonyl)oxy)methyl)piperazin-1-ium iodide [1010] was synthesized using (procedure similar to that used for the synthesis of [1002] using [1001]), (R)-iodomethyl (1-phenylethyl) carbonate [204] and DCM as solvent.




(R)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-((((1-phenylethyl)carbamoyl)oxy)methyl)piperazin-1-ium iodide [1011] was synthesized using (procedure similar to that used for the synthesis of [1002] using [1001]), (R)-iodomethyl (1-phenylethyl)carbamate [206] and DCM as solvent.




(R)-1-(((sec-butoxycarbonyl)oxy)methyl)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium iodide [1012] ] was synthesized using (procedure similar to that used for the synthesis of [1002] using [1001]), (R)-sec-butyl (iodomethyl) carbonate [208] and DCM as solvent.




1-((isobutyryloxy)methyl)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium iodide [1013] was synthesized using (procedure similar to that used for the synthesis of [1002] using [1001]), iodomethyl isobutyrate [25] and DCM as solvent.




1-((((benzyloxy)carbonyl)oxy)methyl)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium iodide [1014] was synthesized using (procedure similar to that used for the synthesis of [1002] using [1001]), benzyl (iodomethyl) carbonate [212] and DCM as solvent.




1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-(((((3-methylbutan-2-yl)oxy)carbonyl)oxy)methyl)piperazin-1-ium iodide [1016] was synthesized using (procedure similar to that used for the synthesis of [1002] using [1001]), iodomethyl (3-methylbutan-2-yl) carbonate [215] and DCM as solvent.




1-(((benzyl(methyl)carbamoyl)oxy)methyl)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium iodide [1017 was synthesized using (procedure similar to that used for the synthesis of [1002] using [1001]), iodomethyl benzyl(methyl)carbamate [217] and DCM as solvent.




(S)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-((((1-phenylethyl)carbamoyl)oxy)methyl)piperazin-1-ium iodide [1018] was synthesized using (procedure similar to that used for the synthesis of [1002]) using [1001]), (S)-iodomethyl (1-phenylethyl)carbamate [219] and DCM as solvent.




1-(((ethoxycarbonyl)oxy)methyl)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium iodide [1019] was synthesized using (procedure similar to that used for the synthesis of [1002]) using [1001]) ethyl (iodomethyl) carbonate [221] and DCM as solvent.




1-(((cyclobutoxycarbonyl)oxy)methyl)-1-methyl-4-(4-((3-methyl-4-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium iodide [1020] was synthesized using (procedure similar to that used for the synthesis of [1002] using [1001]), cyclobutyl (iodomethyl) carbonate [223] and DCM as solvent.




(R)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-((((1-phenylethoxy)carbonyl)oxy)methyl)piperazin-1-ium methanesulfonate [1035] was synthesized using (procedure similar to that used for the synthesis of [1006], using [1005]), Silver methanesulfonate and ACN as solvent.
Example 13: 1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-((2-phenylacetoxy)methyl)piperazin-1-ium trifluoromethanesulfonate [10737.06]




Step 1:

Imatinib, N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide, [1001] (0.5 g, 1.0 mol, 1.0 eq) was dissolved in dry dichloromethane (40 ml) in a 100 ml two-necked round bottom flask, to which was added iodomethyl 2-phenylacetate [1002] (0.28 g, 1.0 mol, 1.0 eq) dissolved in 10 ml DCM dropwise at room temperature. After stirring for 3-4 hours, a yellow precipitate formed. The precipitate was filtered and washed with excess of DCM (dichloromethane) to yield the product, 1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-((2-phenylacetoxy)methyl)piperazin-1-ium iodide [10737.01] as a yellow solid [0.5 g, 64%]; m/z: 643.
Step 2:
To a stirred solution of 1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-((2-phenylacetoxy)methyl)piperazin-1-ium iodide [10737.01] (0.08 g, 0.1 mol, 1.0 eq) in CAN [acetonitrile] (10 ml) was added silver(I) trifluoromethane sulfonate (0.026 g, 0.1 mmol, 1.0 eq) at RT. The reaction mixture was stirred at RT for 30 min. The reaction was filtered to get rid of the silver iodide precipitate. The filtrate was concentrated under vacuum, which was triturated with dry ether (2×5 ml). The ether was removed by decantation and the resulting product was dried under vacuum to yield 1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-((2-phenylacetoxy)methyl)piperazin-1-ium trifluoromethanesulfonate [10737.06] as a light yellow solid [0.045 g, 50%]; m/z: 643.
Synthesis of 10737.02, 10737.04, 10737.07, 10737.08 was achieved by using procedure described in Example 13, step 2 above and using the corresponding silver salts (silver nitrate or silver tosylate or silver tetrafluoroborate or silver mesylate etc.) and 10737.01 as starting material.
Synthesis of 11124.01, 11124.02 and 11124.03 was achieved by using the procedure described in Example 13 using iodomethyl 2-phenylpropanoate instead of iodomethyl 2-phenylacetate [1002].
Example 14: Antiviral Potency of Imatinib Against VEE Virus
Primary antiviral screens were conducted to determine EC50 and cellular toxicity to define a therapeutic index by neutral red assay. Secondary assay determines EC90 using more refined concentrations of inhibitor and virus yield reduction. A low level of virus innoculum that produces maximum cell death at a specified time (≧3 days) were used for virus assay, typically 50-100 CCID50.













TABLE 1








NIAID
Genome
EC50
Therapeutic


Drug
Virus
Virus Family
Category
Type
(micromolar)
Index







imatinib
VEE
alphaviridae
B
ssRNA(+)
6
4









Example 15: Antiviral Potency of Imatinib Against Polyoma Viruses
PCR amplifications were set up in a reaction volume of 50 μL that contained the TaqMan Universal PCR Master Mix (PE Biosystems), 5 μL of tissue lysate, 300 nmol/L each forward and reverse primer, 200 nmol/L probe, 300 μmmol/L dNTPs, 5 mmol/L magnesium, and 1.25 U of Taq Gold polymerase. Thermal cycling was begun with an initial denaturation step at 95° C. for 12 min that was followed by 45 cycles at 95° C. for 15 s (denaturation) and 60° C. for 1 min (reannealing and extension).













TABLE 2









Genome
EC50
Therapeutic



Drug
Virus
Type
(micromolar)
Index






















imatinib
JCV
dsDNA
1.25
10



imatinib
BKV
dsDNA
2.1
10










Pharmacokinetic Properties of the Compounds of the Compounds of the Present Invention

The compounds of the present invention were compared for their pharmacokinetic properties with that of imatinib. The data of the compounds are present at Table 3.
PK Protocol
Female Sprague Dawley (SD) rats 3 per group after overnight fasting were dosed orally (via gavage) with imatinib and its modified drugs in distilled water (5 ml/kg) at a dose level of 3 mg/kg. Blood was collected by serial bleeding at 0.16 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h and 24 h in heparinized tubes. Blood samples were centrifuged at 10,000 rpm for 10 min. at 4° C. to obtain the plasma, which were aspirated into separate labeled tubes and stored at −80° C. 400 ng/ml of Verapamil in acetonitrile was used as the drug extraction solvent for extracting drug from plasma. Extraction solvent was added to plasma was vortexed and shaken on shaker for 10 min, centrifuged at 10000 rpm for 10 min at 4° C. Supernatant was kept for analysis.
Acetonitrile and plasma calibration curves were generated and percentage of imatinib recovery from plasma determined. Quantitative analysis of imatinib levels in each sample was done by liquid chromatography tandem mass spectrometry using multiple reaction monitoring (API3200 LC-MS/MS). Cmax, Tmax, AUC and t1/2 were calculated using Graph Pad PRISM version 5.04.







TABLE 3







PK Parameters for compounds


3 mpk, Distilled Water (Rat, triplicate)










Patent Ref #
AUC (nM*hr)














SR-03 (SPR-618)
523



1006




SR-05
295



(SPR_634)




SR-07 (SPR-619)
470



SR-10 (SPR-631)
1574



1005




SR-11 (SPR-621)
2712



1010




SR-13.1
356



(SPR632)




1013




SR-14*
5233



(SPR-136)




1002




Standard 
1753



(SPR-10627) 




(imatinib)




11124.01
5102







*Vehicle = PEG400






MTS Cell Viability Assay (K562 Cell Line):

The compounds of the present invention were tested for their MTS cell viability assay. The results are presented are Table 4:
K562 cells were the first human immortalised myelogenous leukemia line to be established.
K562 cells are of the erythroleukemia type, and the line is derived from a 53 year old female CML patient. The cells are non-adherent and rounded, are positive for the bcr:abl fusion gene.
K562 cell line is maintained in RPMI1640 with 10% fetal Bovine Serum. 2500 cells/well of K562 cells were plated in 96 well tissue culture plate. Cells were incubated for 48 hours with serially diluted compound (final concentration from 20 μM-0.002 μM) for 48 hr. MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), obtained from Promega was added to the wells and plates were incubated at 370 C in 5% CO2 for 4 hrs. The MTS compound is bio-reduced by cells into a colored formazan product that is soluble in tissue culture medium. The quantity of formazan product as measured by the amount of 490 nm absorbance is directly proportional to the number of living cells in culture. The absorbance was read at 490 nm (Spectramax microplate reader). The Percentage inhibition was calculated and plotted against the concentration of inhibitor and data was fit to Non Linear Regression curve fit (sigmoidal dose response curve with variable slope-four parameters) using Graph pad prism 5.







TABLE 4







Activity of the compounds of the present invention 


in K562 cell lines











% Inhibition—K562 cell line




(myelogenous leukemia)












Compound #
20 uM
2 uM
0.2 uM







1001
67
64
48



1011
70
63
45



1028
76
63
40

## Claims

1. A method of treating a tumoral disease, a bacterial infection caused by Mycobacterium tuberculosis, or a viral infection caused by a Vaccinia virus, a variola virus, a polyoma virus, a Pox virus, a Herpes virus, a cytomegalovirus (CMV), a human immunodeficiency virus, JC virus, BK virus, Simian virus 40 (SV40), Monkeypox virus, Ebola virus, Marburg virus, Bunyavirus, Arenavirus, Alphavirus, Western equine encephalitis (WEE), Flavivirus, West Nile virus or SARS Coronavirus;
wherein the method comprises:
administering to a human a compound of Formula (I) or a pharmaceutically acceptable salt thereof:




wherein:
A and B are independently selected from absent, H or a moiety of Formula (II), with the proviso that at least one of A and B is a moiety of Formula (II);




wherein:
R and R1 are each independently selected from H, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, C1-C8 alkyl or C3-C7 cycloalkyl, wherein in each of the C1-C8 alkyl or C3-C7 cycloalkyl optionally up to three carbon atoms are replaced by a heteroatom group independently selected from O, NR4, S, SO or SO2 (thereby making a heteroalkyl or heterocyclyl substituent), and wherein said C1-C8 alkyl and C3-C7 cycloalkyl are optionally substituted with from 1 to 4 C1-C8 alkyl, alkoxy, aryl or heteroaryl substituents; or R and R1 taken together with the atom to which they are attached form a 3- to 7-membered ring, wherein said 3- to 7-membered ring optionally contains up to two heteroatom groups selected from O, N R4, S, SO or SO2, and is optionally substituted with 1 to 4 alkoxy, F or Cl substituents;
Y, independently for each occurrence, is selected from R2, OR2, NH2, NHR2, or NR2R3;
R2 is selected from alkoxy, aryl, heteroaryl, C1-C8 alkyl or C3-C7 cycloalkyl, wherein in each of the C1-C8 alkyl or C3-C7 cycloalkyl optionally up to three carbon atoms are replaced by a heteroatom group independently selected from O, NR4, S, SO or SO2 (thereby making a heteroalkyl or heterocyclyl substituent), and wherein said C1-C8 alkyl and C3-C7 cycloalkyl are each optionally substituted with from 1 to 4 C1-C8 alkyl, alkoxy, aryl or heteroaryl substituents;
R3 is selected from alkoxy, aryl, heteroaryl, C1-C8 alkyl or C3-C7 cycloalkyl, wherein in each of the C1-C8 alkyl or C3-C7 cycloalkyl optionally up to three carbon atoms are replaced by a heteroatom group independently selected from O, NR4, S, SO or SO2 (thereby making a heteroalkyl or heterocyclyl substituent), and wherein said C1-C8 alkyl and C3-C7 cycloalkyl are each optionally substituted with from 1 to 4 C1-C8 alkyl, alkoxy, aryl or heteroaryl; or
R2 and R3 may be taken together with the nitrogen atom to which they are attached to form a 3- to 7-membered ring, wherein said 3- to 7-membered ring optionally contains up to three heteroatom groups selected from O, NR4, S, SO or SO2, and is optionally substituted with alkoxy, F or Cl;
R4 is, independently for each occurrence, selected from H or C1-C8 alkyl; and
X and X1 are, each independently, an anion or absent, provided that X is absent only when A is absent, and X1 is absent only when B is absent;
provided that neither A nor B is

2. The method of claim 1, comprising treating the bacterial infection or the viral infection.

3. The method of claim 2, wherein the infection is bacterial and is caused by Mycobacterium tuberculosis.

4. The method of claim 2, wherein the infection is viral and is caused by a Vaccinia virus, a variola virus, a polyoma virus, a Pox virus, a Herpes virus, a cytomegalovirus (CMV), a human immunodeficiency virus, JC virus, BK virus, Simian virus 40 (SV40), Monkeypox virus, Ebola virus, Marburg virus, Bunyavirus, Arenavirus, Alphavirus, Western equine encephalitis (WEE), Flavivirus, West Nile virus or SARS Coronavirus.

5. The method of claim 1, wherein the compound is administered orally, nasally, buccally, sublingually, intravenously, transmucosally, rectally, topically, transdermally, subcutaneously, by inhalation, or intrathecally.

6. The method of claim 1, wherein R and R1 are each independently selected from H or C1-C8 alkyl.

7. The method of claim 1, wherein R and R1 are both H.

8. The method of claim 1, wherein R2 and R3 are independently selected from C1-C8 alkyl or aralkyl.

9. The method of claim 8, wherein R2 and R3 are independently selected from methyl, ethyl, isopropyl, tert-butyl, isobutyl, sec-butyl, 3-methylbut-2-yl, 1-phenylethyl, benzyl or cyclobutyl.

10. The method of claim 1, wherein R4, independently for each occurrence, is selected from H or C1-C8 alkyl.

11. The method of claim 1, wherein X and X1 are each independently halide or sulfonate.

12. The method of claim 1, wherein A is a moiety of Formula (II) and B is absent.

13. The method of claim 1, wherein A is absent and B is a moiety of Formula (II).

14. The method of claim 1, wherein Y, independently for each occurrence, is OR2.

15. The method of claim 14, wherein the moiety of Formula (II), independently for each occurrence, is a moiety that would remain after displacing chlorine from:
i. chloromethyl isopropyl carbonate;
ii. benzyl chloromethyl carbonate;
iii. chloromethyl morpholinomethyl carbonate;
iv. chloromethyl isobutyl carbonate;
v. chloromethylmethyl carbonate;
vi. (S)-sec-butyl chloromethyl carbonate;
vii. (R)-sec-butyl chloromethyl carbonate;
viii. chloromethyl ((3S,5R)-3,5-dimethylmorpholino)methyl carbonate;
ix. chloromethyl 2-methylcyclopropyl carbonate;
x. chloromethyl 2-methoxy ethyl carbonate;
xi. chloromethyl propyl carbonate;
xii. chloromethyl cyclobutyl carbonate;
xiii. chloromethyl cyclopropyl carbonate;
xiv. chloromethyl 2,2-dimethylcyclobutyl carbonate;
xv. chloromethyl cyclopentyl carbonate;
xvi. chloromethyl oxetan-3-yl carbonate;
xvii. (S)-chloromethyl tetrahydrofuran-3-yl carbonate;
xviii. chloromethyl cyclohexylmethyl carbonate;
xix. chloromethyl 3-methoxycyclohexyl carbonate;
xx. (R)-chloromethyl tetrahydrofuran-3-yl carbonate;
xxi. chloromethyl ethoxymethyl carbonate;
xxii. chloromethyl oxepan-4-yl carbonate;
xxiii. (1R,2S,4S)-bicyclo[2.2.1]heptan-2-yl chloromethyl carbonate;
xxiv. chloromethyl 2,3-dihydro-1H-inden-1-yl carbonate;
xxv. benzyl chloromethyl carbonate;
xxvi. (S)-chloromethyl 1-phenylethyl carbonate;
xxvii. chloromethyl cyclohexyl carbonate;
xxviii. chloromethyl isobutyl carbonate;
xxix. chloromethyl 4-methylcyclohexyl carbonate;
xxx. chloromethyl 2-(methylthio)ethyl carbonate;
xxxi. chloromethyl 3-methylcyclohexyl carbonate;
xxxii. chloromethylpentan-2-yl carbonate;
xxxiii. chloromethyl neopentyl carbonate;
xxxiv. methyl 1-((chloromethoxy)carbonyloxy)cyclopropanecarboxylate;
xxxv. chloromethyl cyclopropylmethyl carbonate;
xxxvi. chloromethyl 2,2-diethoxyethyl carbonate;
xxxvii. chloromethyl cyclopentylmethyl carbonate;
xxxviii. methyl 2-((chloromethoxy)carbonyloxy)propanoate;
xxxix. (S)-chloromethyl 2,2,4-trimethylcyclopent-3-enyl carbonate;
xl. chloromethyl 1,3-dioxolan-2-yl carbonate;
xli. chloromethyl (2,6-dimethylcyclohexyl)methyl carbonate;
xlii. chloromethyl 2-(tetrahydro-2H-pyran-2-yl)ethyl carbonate;
xliii. chloromethyl(tetrahydro-2H-pyran-4-yl)methyl carbonate;
xliv. chloromethyl tetrahydro-2H-pyran-4-yl carbonate;
xlv. chloromethyl 1-methylcyclopentyl carbonate;
xlvi. chloromethyl 1-cyclopentylethyl carbonate;
xlvii. chloromethyl 3-methylcyclopentyl carbonate;
xlviii. chloromethyl 3,3-dimethylcyclohexyl carbonate;
xlix. chloromethyl 2,5-dimethylcyclohexyl carbonate;
l. chloromethyl 1-(4-methylcyclohexyl)ethyl carbonate;
li. chloromethyl (3-methyloxetan-3-yl)methyl carbonate;
lii. chloromethyl (3-methyloxetan-3-yl)methyl carbonate;
liii. chloromethyl 2-isopropoxyethyl carbonate;
liv. (chloromethyl carbonic) 5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic anhydride;
lv. 4-((chloromethoxy)carbonyloxy)-2-hydroxy-4-oxobutanoic acid;
lvi. chloromethyl 4-formyl-2-methoxyphenyl carbonate;
lvii. chloromethyl 3-oxobutan-2-yl carbonate;
lviii. methyl 4-((chloromethoxy)carbonyloxy)benzoate;
lix. (R)-2-amino-3-((chloromethoxy)carbonyloxy)propanoic acid;
lx. 3-tert-butyl-4-methoxyphenyl chloromethyl carbonate;
lxi. (R)-2-amino-3-(4-((chloromethoxy)carbonyloxy)phenyl)propanoic acid;
lxii. (R)-2-amino-4-((chloromethoxy)carbonyloxy)-4-oxobutanoic acid;
lxiii. (E)-chloromethyl 3,7-dimethylocta-2,6-dienyl carbonate;
lxiv. methyl 4-((chloromethoxy)carbonyloxy)benzoate;
lxv. chloromethyl 2-(4-methylcyclohex-3-enyl)propan-2-yl carbonate;
lxvi. chloromethyl 3,7-dimethylocta-1,6-dien-3-yl carbonate;
lxvii. 4-allyl-2-methoxyphenyl chloromethyl carbonate;
lxviii. chloromethyl (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl carbonate;
lxix. propyl 4-((chloromethoxy)carbonyloxy)benzoate; or
lxx. (E)-chloromethyl 3,7-dimethylocta-2,6-dienyl carbonate.

16. The method of claim 15, wherein the moiety of Formula (II), independently for each occurrence, is a moiety that would remain after displacing chlorine from (S)-sec-butyl chloromethyl carbonate or (R)-sec-butyl chloromethyl carbonate.

17. The method of claim 1, wherein the compound of Formula (I) is represented by Formula (III) or Formula (IV):



where A or B is selected from compounds 101 to 120:







where R5 represents a nitrogen atom of the imatinib moiety linked to A or B; and
X can be iodide, chloride, bromide, mesylate, tosylate, or any other pharmaceutically acceptable anion.

18. The method of claim 17, wherein A or B is selected from compound 111.

19. The method of claim 17, wherein the compound of Formula (III) or Formula (IV) is selected from:
1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)-1-(((morpholine-4-carbonyl)oxy)methyl)piperazin-1-ium iodide;
1-(((isopropoxycarbonyl)oxy)methyl)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium iodide;
1-(((isopropoxycarbonyl)oxy)methyl)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium methane sulfonate;
1-(((isopropoxycarbonyl)oxy)methyl)-1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium p-tolyl sulfonate;
1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)-1-((3-methylbutanoyloxy)methyl)piperazin-1-ium iodide;
1-((isopropylcarbamoyloxy)methyl)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide;
(R)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)-1-(((1-phenylethoxy)carbonyloxy)methyl)piperazin-1-ium iodide;
(R)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)-1-((1-phenylethylcarbamoyloxy)methyl)piperazin-1-ium iodide;
(R)-1-((sec-butoxycarbonyloxy)methyl)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide;
1-methyl-4-(4-(4-methyl-3-(4-(1-((sec-butoxycarbonyloxy)methyl)-pyridinium-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazine iodide;
1-(isobutyryloxymethyl)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide;
1-((benzyloxycarbonyloxy)methyl)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide;
(R)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)-1-(((1-phenylethoxy)carbonyloxy)methyl)piperazin-1-ium iodide;
1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)-1-(((3-methylbutan-2-yloxy)carbonyloxy)methyl)piperazin-1-ium iodide;
1-((benzyl(methyl)carbamoyloxy)methyl)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide;
(S)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)-1-((1-phenylethylcarbamoyloxy)methyl)piperazin-1-ium iodide;
1-((ethoxycarbonyloxy)methyl)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide;
1-((cyclobutoxycarbonyloxy)methyl)-1-methyl-4-(4-(3-methyl-4-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide;
1-methyl-4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-ium methanesulfonate;
1-((2,2-dimethylbutanoyloxy)methyl)-1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)piperazin-1-ium iodide;
1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)-1-((tert-pentyloxycarbonyloxy)methyl)piperazin-1-ium iodide;
1-methyl-4-(4-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenylcarbamoyl)benzyl)-1-((2-phenylacetoxy)methyl)piperazin-1-ium iodide;
4-(4-((3-((4-(1-(((isopropoxycarbonyl)oxy)methyl)pyridin-1-ium-3-yl)pyrimidin-2-yl)amino)-4-methylphenyl)carbamoyl)benzyl)-1-methylpiperazin-1-ium monoiodide monomesylate; or
3-(2-((2-methyl-5-(4-((4-methylpiperazin-1-yl) methyl) benzamido)phenyl)amino)pyrimidin-4-yl)-1-(((morpholine-4-carbonyl)oxy)methyl)pyridin-1-ium monoiodide monomesylate.

20. The method of claim 1, wherein the subject is suffering from a tumoral disease.